SCM
TRVI icon

Soleus Capital Management’s Trevi Therapeutics TRVI Stock Holding History

Soleus Capital Management’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22M Sell
1,179,618
-440,382
-27% -$6.4M 0.76% 38
2026
Q1 		$19.3M Buy
1,620,000
+720,000
+80% +$8.06M 0.78% 35
2025
Q4 		$11.3M Buy
900,000
+875,000
+3,500% +$10.1M 0.42% 48
2025
Q3 		$229K Sell
25,000
-675,000
-96% -$5.06M 0.01% 87
2025
Q2 		$3.83M Buy
+700,000
New +$4.36M 0.25% 62

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Soleus Capital Management's TRVI Position: Q2 2026 in Review

Soleus Capital Management reduced its Trevi Therapeutics (TRVI) stake by 27% in Q2 2026, selling an estimated $6.4M and leaving 1,179,618 shares worth $22M. The position accounts for 0.76% of the portfolio, ranked #38.

Soleus Capital Management first reported a position in TRVI in Q2 2025 and has held it in 5 quarters since. 217 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Soleus Capital Management held 1,179,618 shares of Trevi Therapeutics worth $22M as of Q2 2026.
  • Soleus Capital Management sold 440,382 Trevi Therapeutics shares in Q2 2026, an estimated $6.4M.
  • Trevi Therapeutics made up 0.76% of Soleus Capital Management's portfolio in Q2 2026, its #38 holding.
  • Soleus Capital Management first reported a position in Trevi Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 217 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Soleus Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.